Skip to main content
Premium Trial:

Request an Annual Quote

ActivX Biosciences Raises $20M; Elects Scripps Researcher to Company Board

NEW YORK, July 10 - ActivX Biosciences has raised $20 million in a private placement to develop the company's chemistry-based proteomics platform, the company said Tuesday. 

In addition to Oxford Bioscience Partners, who led the placement, new investors in the company include Vulcan Ventures, CIT Venture Capital, and Novo A/S. Frazier & Company and ProQuest Investments are existing investors in the company.

ActivX also said Tuesday that the company had elected Paul Schimmel, a professor of chemistry and molecular biology at the Scripps Research Institute, as chairman of its board of directors. In other management changes, the company's current president and chief scientific officer, John Kozarich, has taken over the position of CEO from Rob Hillman, who will become the company's chief operating officer. 

At Scripps, Schimmel studies the machinery for decoding genetic information, specifically tRNAs and aminoacyl tRNA synthetases. Schimmel has also helped found Alkermes, a drug-delivery company based in Cambridge, Mass., Cubist Pharmaceuticals, also in Cambridge, and Repligen, a biotechnology company in Needham, Mass.  
The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.